Clinical trials
Terminated trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
734 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 3 |
| 2004 | 5 |
| 2005 | 9 |
| 2006 | 8 |
| 2007 | 28 |
| 2008 | 32 |
| 2009 | 19 |
| 2010 | 32 |
| 2011 | 27 |
| 2012 | 40 |
| 2013 | 29 |
| 2014 | 37 |
| 2015 | 28 |
| 2016 | 33 |
| 2017 | 48 |
| 2018 | 59 |
| 2019 | 67 |
| 2020 | 53 |
| 2021 | 65 |
| 2022 | 56 |
| 2023 | 35 |
| 2024 | 15 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 734 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 61 |
| National Taiwan University Hospital | 37 |
| Pfizer | 31 |
| Hoffmann-La Roche | 28 |
| AstraZeneca | 24 |
| Amgen | 20 |
| Sanofi | 20 |
| Eli Lilly and Company | 17 |
| GlaxoSmithKline | 16 |
| Janssen Research & Development, LLC | 14 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 62 |
| Neoplasms | 44 |
| Carcinoma, Hepatocellular | 34 |
| Neoplasm Metastasis | 26 |
| Breast Neoplasms | 23 |
| Diabetes Mellitus, Type 2 | 21 |
| Squamous Cell Carcinoma of Head and Neck | 19 |
| Stomach Neoplasms | 16 |
| Head and Neck Neoplasms | 15 |
| Schizophrenia | 14 |
Trials
Showing 26 to 50 of 734. Each trial links to its page on Pharma Observatory.
634 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.